Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference

Rhea-AI Summary

Nyxoah (Nasdaq: NYXH) announced its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec 4, 2025.

The session is scheduled for 1:30 p.m. ET and will be available via a live audio webcast on the company investor relations site at investors.nyxoah.com. The presentation will cover recent corporate developments and provide management commentary to investors and analysts.

Nyxoah to Participate in the Piper Sandler 37^th Annual Healthcare Conference

Mont-Saint-Guibert, Belgium – 27 November, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will participate in a fireside chat at the Piper Sandler 37^th Annual Healthcare Conference on Thursday, Dec. 4, 2025. The fireside chat is scheduled at 1:30 p.m. (ET) the same day via webcast.

A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at investors.nyxoah.com.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Contact:

Nyxoah
John Landry
Chief Financial Officer
IR@nyxoah.com

Rémi Renard
Chief Investor Relations & Corporate Communication Officer
IR@nyxoah.com

Attachment

• ENGLISH_NYXH Piper Conf Advisory PR_2025

FAQ

When will Nyxoah (NYXH) present at the Piper Sandler 37th Annual Healthcare Conference?

Nyxoah will present on Thursday, Dec 4, 2025 at 1:30 p.m. ET.

How can investors watch Nyxoah's (NYXH) fireside chat on Dec 4, 2025?

A live audio webcast will be available on Nyxoah's investor relations site: investors.nyxoah.com.

What topics will Nyxoah (NYXH) management cover at the Piper Sandler conference?

Management will discuss recent corporate developments and provide an update on the company's progress and strategy.

Is Nyxoah's (NYXH) Piper Sandler presentation available after the live webcast?

The company typically archives webcasts on its investor relations site for later access; check investors.nyxoah.com after the event.

What time is the Nyxoah (NYXH) webcast for investors in Europe on Dec 4, 2025?

The webcast at 1:30 p.m. ET corresponds to 6:30 p.m. CET on Dec 4, 2025.

Who is presenting for Nyxoah (NYXH) at the Piper Sandler 2025 conference?

The company's management team is scheduled to participate in a fireside chat; specific presenter names were not provided in the announcement.